Citations

Clear

66 citation(s) found for "McCarty, T P".

Development of Complementary Encounter and Patient Decision Aids for Shared Decision Making about Stroke Prevention in Atrial Fibrillation
Jones, Aubrey E. , McCarty, Madeleine M. , Cameron, Kenzie A. , Cavanaugh, Kerri L. , Kansal, Preeti , Guzmán, Adriana , Chen, Emily, Zhong, Lingzi , Hargraves, Ian , Brito, Juan P. , Steinberg, Benjamin A , Montori, Victor M , Ozanne, Elissa M , Cavanaugh, Kerri , Brito, Juan P , Jones, Aubrey E , Steinberg, Benjamin A. , Passman, Rod , Guzman, Adriana, Fagerlin, Angela , Montori, Víctor M. , Noseworthy, Peter A. , Ozanne, Elissa M.

Mayo Clinic

MDM Policy & Practice | June 22, 2023 | Volume: 8 | Issue: 1 | Pages: No page available

10.1177/23814683231178033 | PMID 38178866 Get It

Introduction Decision aids (DAs) are helpful instruments used to support shared decision making (SDM). Patients with atrial fibrillation (AF) face complex decisions regarding stroke prevention strategies. While a few DAs have been made for AF stroke prevention, an encounter DA (EDA) and patient DA (PDA) have not been created to be used in conjunction with each other before. Design Using iterative user-centered design, we developed 2 DAs for anticoagulation choice and stroke prevention in AF. Prototypes were created, and we elicited feedback from patients and experts via observations of encounters, usability testing, and semistructured interviews. Results User testing was done with 33 experts (in AF and SDM) and 51 patients from 6 institutions. The EDA and PDA underwent 1 and 4 major iterations, respectively. Major differences between the DAs included AF pathophysiology and a preparation to meet with the clinician in the PDA as well as different language throughout. Content areas included personalized stroke risk, differences between anticoagulants, and risks of bleeding. Based on user feedback, developers 1) addressed feelings of isolation with AF, 2) improved navigation options, 3) modified content and flow for users new to AF and those experienced with AF, 4) updated stroke risk pictographs, and 5) added structure to the preparation for decision making in the PDA. Limitations These DAs focus only on anticoagulation for stroke prevention and are online, which may limit participation for those less comfortable with technology. Conclusions Designing complementary DAs for use in tandem or separately is a new method to support SDM between patients and clinicians. Extensive user testing is essential to creating high-quality tools that best meet the needs of those using them. Highlights First-time complementary encounter and patient decision aids have been designed to work together or separately. User feedback led to greater structure and different experiences for patients naïve or experienced with anticoagulants in patient decision aids. Online tools allow for easier dissemination, use in telehealth visits, and updating as new evidence comes out.
International Epidemiology of Carbapenemase-Producing Escherichia coli
Boutzoukas, Angelique E , Komarow, Lauren , Chen, Liang , Hanson, Blake , Liu, Zhengyin , Mendoza, Soraya Salcedo, Ordóñez, Karen , Wang, Minggui , Ge, Lizhao , Giri, Abhigya, Hill, Carol , Baum, Keri, Kreiswirth, Barry N. , Patel, Robin , Arias, César A. , Chambers, Henry F. , Fowler, Vance G. , Investigators, Multi-Drug Resistant Organism Network, Souha, S Kanj, Jean, Francois Jabbour, Fujie, Zhang, Judith, J Lok, Robert, A Salata, Martin, Stryjewski, Valentina, Di Castelnuovo, Jose, Millan Oñate Gutierrez, Eric, Cober, Susan, Richter, Deverick, J Anderson, Beth, Evans, Carol, Hill, Heather, Reich, Keri, Baum, Rebekka, Arias, Vance, G Fowler, Karen, Ordoñez, Jesse, T Jacob, Li, Linghua , Barry, Neil, Samit, Desai, Erica, Herc, Ezequiel, Cordova, Maria, R Ponisio, Samuel, Vichez, Marisa, Laëtitia , Sandra, Valderrama, Jairo, Figueroa, Cesar, A Arias, An, Qiang , Diane, Panesso, Kirsten, R., Truc, Thanh, Jiachun, Su, Jiang, Jianping , Ming-gui, Wang, Xu, Xiaogang , Yang, Yang , Jose, M Munita, Maria, Spencer, Thamer, Alenazi, Robert, Alain, Steven, Hersch, Susan, Davies, Charles, Huskins, Kerry, G, Robin, Patel, Suzannah, Schmidt-Malan, Sara, Revolinski, Glenn, Wortmann, Robert, C Kalayjian, Greg, Weston, Belinda, Ostrowsky, Gopi, Patel, Daniel, E Furst, Angela, Kim, Julia, Garcia-Diaz, Soraya, Salcedo, John, Jeffy, Zhengyin, Liu, Andrew, Henderson, David, Louis, Qing, Xie, Keith, S Kaye, Gao, Hainv , Yu, Yunsong , Mary, Waters, Bettina, C Fries, Brandon, Eilertson, Kean, Lee Chew, Nares, Smitasin, Paul, Ananth Tambyah, Jason, Christopher, Anton, Peleg, Marcel, L. Saint, Lan-juan, LI , Lauren, Komarow, Lizhao, Ge, Scott, Evans, Todd, McCarty, Henry, Fitjerald , Omai, B Garner, Lilian, M Abbo, David, van Duin, Ebbing, Lautenbach, Jennifer, Harrington, Yohei, Doi, Darren, W Logan, Blake, Hanson, Jinnethe, Reyes, Maria, Virginia Villegas Botero, Lorena, Diaz, Federico, P., Ritu, Banerjee, Sorabh, Dhar, Michael, Joy S, Zhiyong, Zong, Stryjewski, Martín E. , Villegas, María Virginia , Wang, Minggui , Evans, Scott R , Patel, Robin , van Duin, David , Pérez, Federico , Jiang, Jianping , Boutzoukas, Angelique , Chen, Liang , Villegas, Maria Virginia , Kanj, Souha S. , Paterson, David L. , Evans, Scott , Bonomo, Robert A. , Kreiswirth, Barry N , Arias, César A. , Fowler, Vance G. , Investigators, Multi-Drug Resistant Organism Network, Souha, S Kanj, Fujie, Zhang, Jose, Millan-Onate, Eric, Cober, Barry, N Kreiswirth, Claudia, Manca, Marisa, L Sanchez, An, Q Dinh, Kirsten, Rydell, Hu, Fupin , Maria, Spencer-Sandino, Robert, A Bonomo, Steven, H Marshall, Susan, D Rudin, Glenn, Wortmann, Gopi, Patel, Zhengyin, Liu, David, L Paterson, Qing, Xie, Marimuthu, Kalisvar , Anton, Peleg, Henry, F Chambers, Ebbing, Lautenbach, Jennifer, H Han, Lorena, Diaz, Federico, Perez, Ritu, Banerjee, Zhiyong, Zong

Mayo Clinic

Clinical Infectious Diseases | May 8, 2023 | Volume: 77 | Issue: 4 | Pages: 499-509

10.1093/cid/ciad288 | PMID 37154071 Get It

Abstract Background Carbapenemase-producing (CP) Escherichia coli (CP-Ec) are a global public health threat. We aimed to describe the clinical and molecular epidemiology and outcomes of patients from several countries with CP-Ec isolates obtained from a prospective cohort. Methods Patients with CP-Ec were enrolled from 26 hospitals in 6 countries. Clinical data were collected, and isolates underwent whole-genome sequencing. Clinical and molecular features and outcomes associated with isolates with or without metallo-β-lactamases (MBLs) were compared. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after the index culture. Results Of the 114 CP-Ec isolates in Consortium on resistance against carbapenems in Klebsiella and other Enterobacterales-2 (CRACKLE-2), 49 harbored an MBL, most commonly blaNDM-5 (38/49, 78%). Strong regional variations were noted with MBL-Ec predominantly found among patients in China (23/49). Clinically, MBL-Ec were more often from urine sources (49% vs 29%), less often met criteria for infection (39% vs 58%, P = .04), and had lower acuity of illness when compared with non–MBL-Ec. Among patients with infection, the probability of a better DOOR outcome for a randomly selected patient with MBL-Ec as compared with non–MBL-Ec was 62% (95% CI: 48.2–74.3%). Among infected patients, non–MBL-Ec had increased 30-day (26% vs 0%; P = .02) and 90-day (39% vs 0%; P = .001) mortality compared with MBL-Ec. Conclusions Emergence of CP-Ec was observed with important geographic variations. Bacterial characteristics, clinical presentations, and outcomes differed between MBL-Ec and non–MBL-Ec. Mortality was higher among non-MBL isolates, which were more frequently isolated from blood, but these findings may be confounded by regional variations.
Autograft Demonstrates Superior Outcomes for Revision Anterior Cruciate Ligament Reconstruction When Compared With Allograft: A Systematic Review
Belk, John W. , Smith, John-Rudolph H. , McCarty, Eric C. , Kraeutler, Matthew J. , Smith, John R. , McCarty, Eric C , Smith, John-Rudolph , Littlefield, Connor P. , McCulloch, Patrick C. , Frank, Rachel M

Mayo Clinic

The American Journal of Sports Medicine | March 3, 2023 | Volume: 52 | Issue: 3 | Pages: 859-867

10.1177/03635465231152232 | PMID 36867049 Get It

Background: Multiple studies have compared outcomes among patients undergoing revision anterior cruciate ligament reconstruction (ACLR) with autograft versus allograft, but these data are inconsistently reported and long-term outcomes depending on graft type are yet to be determined. Purpose: To perform a systematic review of clinical outcomes after revision ACLR (rACLR) with autograft versus allograft. Study Design: Systematic review; Level of evidence, 4. Methods: A systematic review of the literature was performed by searching PubMed, the Cochrane Library, and Embase to identify studies that compared the outcomes of patients undergoing rACLR with autograft versus allograft. The search phrase used was autograft allograft revision anterior cruciate ligament reconstruction. Graft rerupture rates, return-to-sports rates, anteroposterior laxity, and patient-reported outcome scores (subjective International Knee Documentation Committee, Tegner, Lysholm, and Knee injury and Osteoarthritis Outcome Score) were evaluated. Results: Eleven studies met inclusion criteria, including 3011 patients undergoing rACLR with autograft (mean age, 28.9 years) and 1238 patients undergoing rACLR with allograft (mean age, 28.0 years). Mean follow-up was 57.3 months. The most common autograft and allograft types were bone–patellar tendon–bone grafts. Overall, 6.2% of patients undergoing rACLR experienced graft retear, including 4.7% in the autograft group and 10.2% in the allograft group ( P < .0001). Among studies that reported return-to-sports rates, 66.2% of patients with an autograft returned to sports as opposed to 45.3% of patients with an allograft ( P = .01). Two studies found significantly greater postoperative knee laxity in the allograft group as compared with the autograft group ( P < .05). Among all patient-reported outcomes, 1 study found 1 significant difference between groups: patients with an autograft had a significantly higher postoperative Lysholm score when compared with patients with an allograft. Conclusion: Patients undergoing revision ACLR with an autograft can be expected to experience lower rates of graft retear, higher rates of return to sports, and less postoperative anteroposterior knee laxity when compared with patients undergoing revision ACLR with an allograft.
Meniscal and Articular Cartilage Predictors of Outcome After Revision ACL Reconstruction: A 6-Year Follow-up Cohort Study
Group, The MARS, Wright, Rick W. , Haas, Amanda K. , Pennings, Jacquelyn S. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Albright, John P., Amendola, Annunziato , Andrish, Jack T. , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Cox, Charles L. , Creighton, R. Alexander , Dahm, Diane L., Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, LTC Steven J., Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., York, James J. , Svoboda, Steven J. , McCarty, Eric C , Group, The MARS, Huston, Laura J. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , Brophy, Robert H. , Campbell, John , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Marx, Robert G. , McAllister, David R. , Owens, Brett D. , Shea, Kevin G. , Sherman, Orrin H. , Vidal, Armando F. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | February 3, 2023 | Volume: 51 | Issue: 3 | Pages: 605-614

10.1177/03635465231151389 | PMID 36734487 Get It

Background: Meniscal and chondral damage is common in the patient undergoing revision anterior cruciate ligament (ACL) reconstruction. Purpose: To determine if meniscal and/or articular cartilage pathology at the time of revision ACL surgery significantly influences a patient’s outcome at 6-year follow-up. Study Design: Cohort study; Level of evidence, 3. Methods: Patients undergoing revision ACL reconstruction were prospectively enrolled between 2006 and 2011. Data collection included baseline demographics, surgical technique, pathology, treatment, and scores from 4 validated patient-reported outcome instruments: International Knee Documentation Committee (IKDC), Knee injury and Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Marx Activity Rating Scale. Patients were followed up at 6 years and asked to complete the identical set of outcome instruments. Regression analysis assessed the meniscal and articular cartilage pathology risk factors for clinical outcomes 6 years after revision ACL reconstruction. Results: An overall 1234 patients were enrolled (716 males, 58%; median age, 26 years). Surgeons reported the pathology at the time of revision surgery in the medial meniscus (45%), lateral meniscus (36%), medial femoral condyle (43%), lateral femoral condyle (29%), medial tibial plateau (11%), lateral tibial plateau (17%), patella (30%), and trochlea (21%). Six-year follow-up was obtained on 79% of the sample (980/1234). Meniscal pathology and articular cartilage pathology (medial femoral condyle, lateral femoral condyle, lateral tibial plateau, trochlea, and patella) were significant drivers of poorer patient-reported outcomes at 6 years (IKDC, KOOS, WOMAC, and Marx). The most consistent factors driving outcomes were having a medial meniscal excision (either before or at the time of revision surgery) and patellofemoral articular cartilage pathology. Six-year Marx activity levels were negatively affected by having either a repair/excision of the medial meniscus (odds ratio range, 1.45-1.72; P≤ .04) or grade 3-4 patellar chondrosis (odds ratio, 1.72; P = .04). Meniscal pathology occurring before the index revision surgery negatively affected scores on all KOOS subscales except for sports/recreation ( P < .05). Articular cartilage pathology significantly impaired all KOOS subscale scores ( P < .05). Lower baseline outcome scores, higher body mass index, being a smoker, and incurring subsequent surgery all significantly increased the odds of reporting poorer clinical outcomes at 6 years. Conclusion: Meniscal and chondral pathology at the time of revision ACL reconstruction has continued significant detrimental effects on patient-reported outcomes at 6 years after revision surgery.
Descriptive Characteristics and Outcomes of Patients Undergoing Revision Anterior Cruciate Ligament Reconstruction With and Without Tunnel Bone Grafting
Group, MARS, DeFroda, Steven F. , Wright, Rick W. , Huston, Laura J. , Pennings, Jacquelyn S. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Albright, John P., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Bechler, Jeffery R., Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Brophy, Robert H. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M. , Cox, Charles L. , Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Garofoli, Elizabeth A. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C. , Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCarty, Eric C. , McCormack, Robert G. , Miller, Bruce S. , Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Slauterbeck, James R., Smith, Matthew V. , Spang, Jeffrey T. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Williams, James S., Wolcott, Michelle L., Wolf, Brian R. , York, James J. , Brophy, Robert H. , McCarty, Eric C , Group, MARS, Owens, Brett D. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Benjamin, C. , McAllister, David R. , Shea, Kevin G. , Sherman, Orrin H.

Mayo Clinic

The American Journal of Sports Medicine | July 14, 2022 | Volume: 50 | Issue: 9 | Pages: 2397-2409

10.1177/03635465221104470 | PMID 35833922 Get It

Background: Lytic or malpositioned tunnels may require bone grafting during revision anterior cruciate ligament reconstruction (rACLR) surgery. Patient characteristics and effects of grafting on outcomes after rACLR are not well described. Purpose: To describe preoperative characteristics, intraoperative findings, and 2-year outcomes for patients with rACLR undergoing bone grafting procedures compared with patients with rACLR without grafting. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 1234 patients who underwent rACLR were prospectively enrolled between 2006 and 2011. Baseline revision and 2-year characteristics, surgical technique, pathology, treatment, and patient-reported outcome instruments (International Knee Documentation Committee [IKDC], Knee injury and Osteoarthritis Outcome Score [KOOS], Western Ontario and McMaster Universities Osteoarthritis Index, and Marx Activity Rating Scale [Marx]) were collected, as well as subsequent surgery information, if applicable. The chi-square and analysis of variance tests were used to compare group characteristics. Results: A total of 159 patients (13%) underwent tunnel grafting—64 (5%) patients underwent 1-stage and 95 (8%) underwent 2-stage grafting. Grafting was isolated to the femur in 31 (2.5%) patients, the tibia in 40 (3%) patients, and combined in 88 patients (7%). Baseline KOOS Quality of Life (QoL) and Marx activity scores were significantly lower in the 2-stage group compared with the no bone grafting group ( P≤ .001). Patients who required 2-stage grafting had more previous ACLRs ( P < .001) and were less likely to have received a bone–patellar tendon–bone or a soft tissue autograft at primary ACLR procedure ( P≤ .021) compared with the no bone grafting group. For current rACLR, patients undergoing either 1-stage or 2-stage bone grafting were more likely to receive a bone–patellar tendon–bone allograft ( P≤ .008) and less likely to receive a soft tissue autograft ( P≤ .003) compared with the no bone grafting group. At 2-year follow-up of 1052 (85%) patients, we found inferior outcomes in the 2-stage bone grafting group (IKDC score = 68; KOOS QoL score = 44; KOOS Sport/Recreation score = 65; and Marx activity score = 3) compared with the no bone grafting group (IKDC score = 77; KOOS QoL score = 63; KOOS Sport/Recreation score = 75; and Marx activity score = 7) ( P≤ .01). The 1-stage bone graft group did not significantly differ compared with the no bone grafting group. Conclusion: Tunnel bone grafting was performed in 13% of our rACLR cohort, with 8% undergoing 2-stage surgery. Patients treated with 2-stage grafting had inferior baseline and 2-year patient-reported outcomes and activity levels compared with patients not undergoing bone grafting. Patients treated with 1-stage grafting had similar baseline and 2-year patient-reported outcomes and activity levels compared with patients not undergoing bone grafting.
Central Nervous System Metabolism in Autism, Epilepsy and Developmental Delays: A Cerebrospinal Fluid Analysis
Brister, Danielle , Werner, Brianna, Gideon, Geoffrey, McCarty, Patrick J. , Lane, Alison L., Burrows, Brian T., McLees, Sallie E., Adelson, P. David , Arango, Jorge , Marsh, W., Flores, Angelea, Ly, Ngoc Han, Flood, Madison, Brown, Danni, Carpentieri, David , Jin, Yan , Gu, Haiwei , Frye, Richard E. , Marsh, William, Carpentieri, David , Frye, Richard E , Pankratz, Matthew T

Mayo Clinic

Metabolites | April 21, 2022 | Volume: 12 | Issue: 5 | Pages: 371

10.3390/metabo12050371 | PMID 35629876 Get It

Neurodevelopmental disorders are associated with metabolic pathway imbalances; however, most metabolic measurements are made peripherally, leaving central metabolic disturbances under-investigated. Cerebrospinal fluid obtained intraoperatively from children with autism spectrum disorder (ASD, n = 34), developmental delays (DD, n = 20), and those without known DD/ASD (n = 34) was analyzed using large-scale targeted mass spectrometry. Eighteen also had epilepsy (EPI). Metabolites significantly related to ASD, DD and EPI were identified by linear models and entered into metabolite–metabolite network pathway analysis. Common disrupted pathways were analyzed for each group of interest. Central metabolites most involved in metabolic pathways were L-cysteine, adenine, and dodecanoic acid for ASD; nicotinamide adenine dinucleotide phosphate, L-aspartic acid, and glycine for EPI; and adenosine triphosphate, L-glutamine, ornithine, L-arginine, L-lysine, citrulline, and L-homoserine for DD. Amino acid and energy metabolism pathways were most disrupted in all disorders, but the source of the disruption was different for each disorder. Disruption in vitamin and one-carbon metabolism was associated with DD and EPI, lipid pathway disruption was associated with EPI and redox metabolism disruption was related to ASD. Two microbiome metabolites were also detected in the CSF: shikimic and cis-cis-muconic acid. Overall, this study provides increased insight into unique metabolic disruptions in distinct but overlapping neurodevelopmental disorders.
Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101
Brunstein, Claudio G. , O’Donnell, Paul V. , Logan, Brent R. , Horowitz, Mary M. , Horwitz, Mitchell E. , Karanes, Chatchada , Magenau, John, Malone, Adriana K. , McCarty, John M. , Morris, Lawrence E. , Rezvani, Andrew R. , Rybka, Witold B. , Salit, Rachel B. , Vasu, Sumithira , Fuchs, Ephraim J. , Costa, Luciano J. , Cutler, Corey S. , Craig, Michael , Hogan, William J. , McGuirk, Joseph P. , Eapen, Mary

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 3956-3956

10.1182/blood-2021-145527 Get It

Abstract BACKGROUND: Our group recently reported on the results of Blood and Marrow Transplant (BMT) Clinical Trials Network (CTN) 1101 a randomized comparison between double umbilical cord blood (dUCB) and haploidentical bone marrow (haplo) with post-transplant cyclophosphamide (ptCy) in the nonmyeloablative setting that showed similar progression free survival (PFS) between the two treatment groups, but lower non-relapse mortality (NRM) and better of overall survival (OS) in the haplo arm. In this secondary analysis we sought to investigate if transplant center experience with haplo and or cord blood HCT had an impact on outcomes. PATIENTS AND METHODS: All patient randomized in BMT CTN 1101 were included. In order to determine the transplant center experience with either haplo or dUCB we queried the Center for International Blood and Marrow Transplant Research (CIBMTR) for number of transplants with each platform in the year prior to initiation of the study. Centers were then grouped as dUCB center (&gt; 10 dUCB, n=117, 10 centers), Haplo center (&gt;10 haplo and ≤10 dUCB, n=110, 2 centers), and ≤10 haplo and ≤10 dUCB HCTs (other center, n=140, 21 centers). Further analysis considered the alternative cut-off for haplo (&gt; 5 vs ≤ 5) experience, and considered the outcomes based on the donor experience vs. others (e.g. dUCB &gt; 10 vs. ≤ 10; haplo &gt; 5 vs. ≤ 5). RESULTS: The effect of center experience on HCT outcomes shown in Figure, below . After adjusting for age, Karnofsky performance score and, disease risk index we found that there was no difference in outcomes between haplo and dUCB for centers that were experienced with dUCB or had limited to no experience with either dUCB or haplo. In contrast, in centers that were primarily experienced with haplo had better outcomes with this donor type, as compared to dUCB. The higher risk of treatment failure (relapse or death) and overall mortality in dUCB in haplo experienced centers was driven by significantly higher risk of relapse. We then considered the transplant experience with each of the donor types separately. In transplant centers that had performed &gt; 10 dUCB, there were similar outcomes for recipients of both dUCB and haplo. Similarly, centers that had ≤ 5 haplo HCTs had no difference in outcomes between donor types suggesting an overlap with centers that had performed &gt; 10 dUCB HCTs. Overall mortality was higher among dUCB recipients in centers that had performed ≤ 10 dUCB. Notably, the hazard ratio of non-relapse mortality favored haplo in all four donor experience type of transplant center, albeit not statistically significant. CONCLUSION: Except for dUCB recipients in centers with &lt; 10 dUCB/year had worse overall mortality, primarily driven by relapse, the transplant center experience in the year prior to the initiation of BMT CTN 1101 had limited impact on the outcomes of this randomized clinical trial. Figure 1 Figure 1. Disclosures Brunstein: NANT: Research Funding; FATE: Research Funding; GamidaCell: Research Funding; BlueRock: Research Funding; AlloVir: Consultancy. Costa: Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria, Speakers Bureau; Pfizer: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria. Cutler: Deciphera: Consultancy; Cimeio: Consultancy; Editas: Consultancy; Kadmon: Consultancy; Pfizer: Consultancy; Mallinckrodt: Consultancy; CareDx: Consultancy; Incyte: Consultancy; Omeros: Consultancy; Syndax: Consultancy; Mesoblast: Consultancy; Jazz: Consultancy. Horowitz: Sobi: Research Funding; Regeneron: Research Funding; Orca Biosystems: Research Funding; Tscan: Research Funding; Xenikos: Research Funding; Miltenyi Biotech: Research Funding; Stemcyte: Research Funding; Medac: Research Funding; Vor Biopharma: Research Funding; Kite/Gilead: Research Funding; Janssen: Research Funding; Pharmacyclics: Research Funding; Kiadis: Research Funding; Seattle Genetics: Research Funding; Mesoblast: Research Funding; GlaxoSmithKline: Research Funding; Sanofi: Research Funding; Pfizer, Inc: Research Funding; Omeros: Research Funding; Magenta: Consultancy, Research Funding; Jazz Pharmaceuticals: Research Funding; Vertex: Research Funding; Genentech: Research Funding; Takeda: Research Funding; Novartis: Research Funding; Shire: Research Funding; Gamida Cell: Research Funding; Daiicho Sankyo: Research Funding; CSL Behring: Research Funding; Chimerix: Research Funding; Bristol-Myers Squibb: Research Funding; bluebird bio: Research Funding; Astellas: Research Funding; Amgen: Research Funding; Allovir: Consultancy; Actinium: Research Funding. Horwitz: Gamida Cell: Research Funding. McGuirk: Novartis: Research Funding; Magenta Therapeutics: Consultancy, Honoraria, Research Funding; EcoR1 Capital: Consultancy; Pluristem Therapeutics: Research Funding; Novartis: Research Funding; Bellicum Pharmaceuticals: Research Funding; Astelllas Pharma: Research Funding; Gamida Cell: Research Funding; Fresenius Biotech: Research Funding; Allovir: Consultancy, Honoraria, Research Funding; Juno Therapeutics: Consultancy, Honoraria, Research Funding; Kite/ Gilead: Consultancy, Honoraria, Other: travel accommodations, expense, Kite a Gilead company, Research Funding, Speakers Bureau. Rezvani: US Department of Justice: Consultancy; Kaleido: Other: One-time scientific advisory board; Nohla Therapeutics: Other: One-time scientific advisory board; Pharmacyclics-Abbvie: Research Funding. Rybka: Spark Therapeutics: Consultancy; Merck: Consultancy. Vasu: Kiadis, Inc.: Research Funding; Boehringer Ingelheim: Other: Travel support; Seattle Genetics: Other: travel support; Omeros, Inc.: Membership on an entity's Board of Directors or advisory committees.
Adefovir dipivoxil for chronic hepatitis B
Garg, Sushil Kumar , Alam, Shaan E., Kongnyuy, Eugene J, Njei, Basile , McCarty, Thomas R.

Mayo Clinic

Cochrane Database of Systematic Reviews | November 2, 2021 | Volume: 2021 | Issue: 11 | Pages: No page available

10.1002/14651858.cd009521.pub2 Get It

Resting State Functional Magnetic Resonance Imaging Elucidates Neurotransmitter Deficiency in Autism Spectrum Disorder
McCarty, Patrick J. , Sussman, Bethany L. , Wyckoff, Sarah N. , Jensen, Amanda , Bunch, Raymond, Boerwinkle, Varina L. , Frye, Richard E. , Pines, Andrew R. , Sussman, Bethany L , Wyckoff, Sarah N , Frye, Richard E , Jensen, Amanda

Mayo Clinic

Journal of Personalized Medicine | September 28, 2021 | Volume: 11 | Issue: 10 | Pages: 969

10.3390/jpm11100969 | PMID 34683111 Get It

Resting-state functional magnetic resonance imaging provides dynamic insight into the functional organization of the brains’ intrinsic activity at rest. The emergence of resting-state functional magnetic resonance imaging in both the clinical and research settings may be attributed to recent advancements in statistical techniques, non-invasiveness and enhanced spatiotemporal resolution compared to other neuroimaging modalities, and the capability to identify and characterize deep brain structures and networks. In this report we describe a 16-year-old female patient with autism spectrum disorder who underwent resting-state functional magnetic resonance imaging due to late regression. Imaging revealed deactivated networks in deep brain structures involved in monoamine synthesis. Monoamine neurotransmitter deficits were confirmed by cerebrospinal fluid analysis. This case suggests that resting-state functional magnetic resonance imaging may have clinical utility as a non-invasive biomarker of central nervous system neurochemical alterations by measuring the function of neurotransmitter-driven networks. Use of this technology can accelerate and increase the accuracy of selecting appropriate therapeutic agents for patients with neurological and neurodevelopmental disorders.